Eli, a Montreal, Canada-based company enabling women to own their fertility and health decisions with a novel hormone tracking technology, raised $1.5m in seed funding.
The round, which brings total funding since its creation in mid-2019 to $2.1m, was led by Vectr Ventures with the participation of 2048 Ventures, Real Ventures, Techstars, Panache Ventures, Ramen Ventures, MEDTEQ+, and serial entrepreneur Steven Arless, who also joined the board.
The company will use the new capital for product development, clinical validations with independent medical centers, and first strategic sales and continue working with academic institutions to push women’s health research forward.
Led by Marina Pavlovic Rivas, CEO and co-founder, Eli is developing a device that uses saliva to capture hormone fluctuations at home, and an app that provides information daily based on each user’s evolving hormonal profile.
FinSMEs
21/01/2021